专家文章 | 崔一民

搜索
登录

热心肠智库专家文章 | 崔一民

2023

CAA Phase 1 Multiple Dose Study of Tirzepatide in Chinese Patients with Type 2 Diabetes

ADV THER, 10.1007/s12325-023-02536-8

CAGenetic variants influenced the risk of bleeding and pharmacodynamics of rivaroxaban in patients with nonvalvular atrial fibrillation: A multicentre prospective cohort study

CLIN TRANSL MED, 10.1002/ctm2.1263

CASafety, Tolerability, and Pharmacokinetics of Recombinant Human Neuregulin-1 in Healthy Chinese Subjects

AM J CARDIOVASC DRUG, 10.1007/s40256-023-00585-6

CAA novel immunogenic cell death-related subtype classification and risk signature for predicting prognosis and immunotherapy efficacy in gastric cancer

Front Immunol, 10.3389/fimmu.2023.1162876

CAPopulation pharmacokinetic analysis and dosing regimen optimization of teicoplanin in critically ill patients with sepsis

FPHAR, 10.3389/fphar.2023.1132367

FACAHematologic side effects of immune checkpoint inhibitor with or without chemotherapy in patients with advanced and metastatic gastrointestinal cancer: A systematic review and network meta-analysis of phase 3 trials

FPHAR, 10.3389/fphar.2023.1163971

CAIdentification of genetic biomarkers associated with pharmacokinetics and pharmacodynamics of apixaban in Chinese healthy volunteers

EXPERT OPIN DRUG MET, 10.1080/17425255.2023.2184344

CANew perspectives on the induction and acceleration of immune-associated thrombosis by PF4 and VWF

Front Immunol, 10.3389/fimmu.2023.1098665

CADiscovery of C19-9 as a novel non-RGD inhibitor of αvβ3 to overcome enzalutamide resistance in castration-resistant prostate cancer

SIGNAL TRANSDUCT TAR, 10.1038/s41392-022-01236-z

CAThe challenges and opportunities of αvβ3-based therapeutics in cancer: From bench to clinical trials

Pharmacol Res, 10.1016/j.phrs.2023.106694

CAIntegrated Pharmacokinetics/Pharmacodynamics Model and Simulation of the Ticagrelor Effect on Patients with Acute Coronary Syndrome

CLIN PHARMACOKINET, 10.1007/s40262-022-01208-0

CAUrinary Eubacterium sp. CAG:581 Promotes Non-Muscle Invasive Bladder Cancer (NMIBC) Development through the ECM1/MMP9 Pathway

Cancers, 10.3390/cancers15030809

CATargeting integrin pathways: mechanisms and advances in therapy

SIGNAL TRANSDUCT TAR, 10.1038/s41392-022-01259-6

2022

CACirculating miR-320a-3p and miR-483-5p level associated with pharmacokinetic-pharmacodynamic profiles of rivaroxaban

HUM GENOMICS, 10.1186/s40246-022-00445-5

CAGenetic variations in relation to bleeding and pharmacodynamics of dabigatran in Chinese patients with nonvalvular atrial fibrillation: A nationwide multicentre prospective cohort study

CLIN TRANSL MED, 10.1002/ctm2.1104

CADrug-induced fall risk in older patients: A pharmacovigilance study of FDA adverse event reporting system database

FPHAR, 10.3389/fphar.2022.1044744

CAThe role of Angiogenesis and remodeling (AR) associated signature for predicting prognosis and clinical outcome of immunotherapy in pan-cancer

Front Immunol, 10.3389/fimmu.2022.1033967

CAPharmacokinetics and Safety of Vedolizumab Following Administration of a Single Intravenous Dose in Healthy Chinese Subjects

EUR J DRUG METAB PH, 10.1007/s13318-022-00804-6

CASafety and immunogenicity of a bivalent SARS-CoV-2 recombinant protein vaccine, SCTV01C in unvaccinated adults: A randomized, double-blinded, placebo-controlled, phase I clinical trial

J INFECT, 10.1016/j.jinf.2022.11.008

CAPopulation pharmacokinetic analysis for dabigatran etexilate in Chinese patients with non-valvular atrial fibrillation

Front Cardiovasc Med, 10.3389/fcvm.2022.998751